A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Generalized Myasthenia Gravis
About this trial
This is an interventional treatment trial for Generalized Myasthenia Gravis focused on measuring generalized Myasthenia Gravis, gMG, rozanolixizumab
Eligibility Criteria
Inclusion Criteria: Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG) Study participant is willing to perform and capable of performing home self-administration Study participant is considered by the investigator for additional rozanolixizumab treatment with the posology proposed in this study. Body weight ≥35 kg Study participants may be male or female Exclusion Criteria: Study participant has a known hypersensitivity to other anti-Fc receptor (FcRn) medications, to any components of the study medication, to any of the excipients (including polysorbate 80), or has a known history of hyperprolinemia, since both polysorbate 80 and L-proline are constituents of the rozanolixizumab formulation Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current or history of nontuberculous mycobacterial infection (NTMBI) Study participant has a clinically relevant active infection or a history of serious infection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline Visit The study participant previously participated in any rozanolixizumab MG study and met any mandatory withdrawal criteria (unless the reason is directly related to MG0020 participation) or mandatory study drug discontinuation criteria. Study participant has received a live vaccination within 4 weeks before starting treatment, or a Bacillus Calmette-Guérin (BCG) vaccine within 1 year before starting treatment; or intends to have a live vaccination during the course of the study or within 8 weeks following the last dose of rozanolixizumab Study participant with severe (defined as Grade 3 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
Sites / Locations
- Mg0020 50092Recruiting
- Mg0020 50099Recruiting
- Mg0020 50561Recruiting
- Mg0020 50090Recruiting
- Mg0020 50560Recruiting
- Mg0020 50069Recruiting
- Mg0020 20161Recruiting
- Mg0020 20163Recruiting
- Mg0020 20165Recruiting
- Mg0020 20305Recruiting
- Mg0020 40135Recruiting
- Mg0020 40140Recruiting
- Mg0020 40177Recruiting
- Mg0020 40144Recruiting
- Mg0020 40146Recruiting
- Mg0020 40150Recruiting
- Mg0020 20068Recruiting
- Mg0020 20078Recruiting
- Mg0020 20077Recruiting
- Mg0020 20076Recruiting
- Mg0020 40155Recruiting
- Mg0020 40727Recruiting
- Mg0020 40153Recruiting
- Mg0020 40729Recruiting
- Mg0020 40160Recruiting
- Mg0020 40267Recruiting
- Mg0020 40308Recruiting
- Mg0020 40168Recruiting
- Mg0020 40163Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Rozanolixizumab Sequence 1: Syringe Driver - Manual Push
Rozanolixizumab Sequence 2: Manual Push - Syringe Driver
Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.